申请人:Tedford E. Clark
公开号:US20060035883A1
公开(公告)日:2006-02-16
The present invention discloses novel 5-HT receptor binding agents of Formula 3,
wherein X is —CH or —N—. Y is selected from the group consisting of —CR
10
R
11
, —NR
12
, —O—, —S—, —SO—, and —SO
2
—. R
1
to R
12
are various substituents selected to optimize the physicochemical and biological properties such as receptor binding, receptor selectivity, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 3. These include hydrogen, alkyl, acyl, hydroxyl, hydroxyalkyl, aryl, amino, aminoalkyl, alkoxyl, aryloxyl, carboxyl, alkoxycarbonyl, halogen, cyano, and other suitable electron donating or electron withdrawing groups. R
2
and R
3
, R
3
and R
4
, or R
5
and R
6
may optionally be tethered together to form fused alicyclic or heterocyclic ring. R
1
and R
2
, R
4
and R
5
, or R
6
and R
7
may also optionally be tethered together to form spiro carbo- or heterocyclic ring.